Author

Yitong Yang

University Health NetworkORCID 0000-0002-5953-9858Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

John Edgar DickiD· 2 shared Mark David MindeniD· 2 shared Steven M. ChaniD· 2 shared Aaron David SchimmeriD· 1 shared Aarushi GuptaiD· 1 shared Abdula MaheriD· 1 shared Alex C.H. LiuiD· 1 shared Andrea ArrudaiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

John Edgar DickORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 12, 2026

CD59 organizes the plasma membrane to sustain oncogenic Ras-MAPK signaling and is a targetable vulnerability in acute myeloid leukemia

Abdula Maher, Dhanoop Manikoth Ayyathan, Séverine Cathelin…·Steven M. Chan

This study identifies CD59 as a critical regulator of Ras-MAPK signaling in AML, showing its depletion impairs leukemic growth and identifies rILYd4 as a potential therapeutic target.

DOI 10.64898/2026.08.11.744285

humanbulk RNA-seq

Cancer BiologyCancer ResearchPeer-reviewedNov 11, 2025

Hematopoietic Tet2 inactivation enhances the response to checkpoint blockade immunotherapy

Vincent Rondeau, Suraj Bansal, Marco M. Buttigieg…·Robert J. Vanner

This study shows that hematopoietic Tet2 inactivation improves immune checkpoint blockade response in mice and is associated with better clinical outcomes in melanoma patients with TET2-driven clonal hematopoiesis.

12 citationstop 3%

mousehuman